Morgan Stanley analyst Judah Frommer raised the firm’s price target on Celldex (CLDX) to $44 from $43 and keeps an Overweight rating on the shares following the company’s Q4 update. The risk/reward remains “favorable” as the company progresses its lead indication and reads out additional data in 2026 for both barzo and CDX-622, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex price target raised to $68 from $58 at Stifel
- Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
- Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
- Celldex reports Q4 EPS ($1.22), consensus ($1.00)
- Celldex completes enrollment in Phase 3 studies of barzolvolimab